BioProcess International Announces the Launching of BioProcess Insider ― Business News and Analysis for the Biopharmaceutical Industry

Launching in June 2018, BioProcess Insider, a digital information portal will deliver the latest financial and business news and expert insider views impacting the research, development, and manufacturing of biologics directly to your inbox including global markets, deal-making, facilities and capacities, upstream and downstream processing, therapeutic classes, and international regulations.

BioProcess International (BPI), the biopharmaceutical industry’s leading business-to-business information platform, announced the June 2018 launch of BioProcess Insider, a digitally delivered news and analysis platform dedicated to providing biopharmaceutical manufacturers, suppliers, and decision makers with latest business news, financial information and perspectives influencing the commercialization of biologicals.

Created and edited by veteran journalist Dan Stanton, every edition of BioProcess Insider provides expert and insider perspective on the latest financial movements and M&A activity; the newest technology purchases and capacity investments; regulations affecting the bioprocessing sector; global market actions and reactions; and insider perspectives on the next big industry trends.

“The addition of Dan Stanton, an industry influencer and disruptor, to BioProcess International‘s editorial staff, combined with the launching of a dedicated business newsletter and Web portal, expands BPI’s traditional scientific platform. It provides BioProcess International with the ability to complete the information chain and help accelerate biopharmaceutical commercialization,” said Brian Caine, BPI co-founder and publisher.

“Having launched and edited leading online biopharmaceutical publications over my career, I am looking forward to working with the BioProcess International team to extend BPI’s industry-leading editorial coverage to report on how the science and business must work together to ensure commercial efficiency and success,” added Dan Stanton, BioProcess Insider’s founding editor.

 

Leave a Reply